EUVIMEDEUVIMED entdecken
Systematische Übersicht

Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma

Francesc Bosch, John Kuruvilla, Theodoros P Vassilakopoulos, Danilo Di Maio, Michael C Wei, Marie-Helene Blanchet Zumofen, Loretta J Nastoupil

Clinical Lymphoma Myeloma and Leukemia · 2024-02 · 24 (2) · 105-121

DOI: 10.1016/j.clml.2023.09.007 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-02. Verfasst von Francesc Bosch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: fbosch@…. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antineoplastic Agents, Antibodies, Bispecific, Benzamides. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularAntineoplastic AgentsAntibodies, BispecificBenzamidesBiphenyl CompoundsMorpholinesPyridonesHumansPhosphatidylinositol 3-KinasesNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Anti-CD20 antibodiesBispecific antibodyCART therapyComparative efficacyNon-Hodgkin lymphoma

Substanzen

tazemetostatPhosphatidylinositol 3-KinasesAntineoplastic AgentsAntibodies, BispecificBenzamidesBiphenyl CompoundsMorpholinesPyridones

Autor:innen und Institutionen

  • Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: fbosch@vhebron.net.
  • Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Department of Haematology and Bone Marrow Transplantation, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • F. Hoffmann-La Roche, Basel, Switzerland.
  • Genentech, South San Francisco, CA.
  • The University of Texas MD Anderson Cancer Center, Houston, TX.

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Bosch, F., Kuruvilla, J., Vassilakopoulos, T. P., Maio, D. D., Wei, M. C., Zumofen, M. B., & Nastoupil, L. J. (2024). Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 24(2), 105-121. https://doi.org/10.1016/j.clml.2023.09.007

Vancouver

Bosch F, Kuruvilla J, Vassilakopoulos TP, Maio DD, Wei MC, Zumofen MB, et al. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2024;24(2):105-121. doi:10.1016/j.clml.2023.09.007

BibTeX
@article{Bosch2024,
  author = {Bosch, Francesc and Kuruvilla, John and Vassilakopoulos, Theodoros P and Maio, Danilo Di and Wei, Michael C and Zumofen, Marie-Helene Blanchet and Nastoupil, Loretta J},
  title = {Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  volume = {24},
  number = {2},
  pages = {105--121},
  doi = {10.1016/j.clml.2023.09.007}
}
Kostenlos starten →